RIGEL PHARMACEUTICALS INC 8-K

What Happened
Rigel Pharmaceuticals announced on May 11, 2026 that it entered a License Agreement with Arvinas, Arvinas Operations, Arvinas Estrogen Receptor and Pfizer to obtain an exclusive, royalty-bearing worldwide license to develop, manufacture and commercialize VEPPANU (vepdegestrant). VEPPANU is FDA‑approved in the U.S. for adults with ER+, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer after progression on at least one endocrine therapy.

Key Details

• Upfront and near-term payments: $70 million upfront plus $15 million upon completion of certain transition activities.
• Milestones and royalties: Up to $320 million in regulatory and sales milestones (including up to $60M for regulatory milestones and up to $260M tied to net sales); tiered royalties on annual net sales in the mid‑teens to mid‑twenties percent range, subject to reductions and adjustments.
• Cost sharing and transition: Rigel will reimburse certain Licensor development costs up to $40 million; Pfizer will remain responsible for certain ongoing development activities during transition.
• Scope and term: Exclusive worldwide rights; Rigel primarily responsible for development and commercialization; license lasts product-by-product and country-by-country until applicable royalty terms expire, then becomes fully paid‑up and perpetual. Agreement effectiveness is subject to expiration/termination of the Hart‑Scott‑Rodino waiting period.

Why It Matters
This deal gives Rigel commercial control of an FDA‑approved breast cancer therapy, potentially adding a near‑term revenue opportunity if VEPPANU is successfully launched and sold. The agreement requires significant upfront and contingent payments and ongoing royalty obligations, which will affect Rigel’s cash outflows and margin profile as revenue grows. Milestone and sales payments provide upside tied to commercial performance, while transition and reimbursement obligations (up to $40M) and the HSR wait are near‑term implementation considerations for investors.